AstraZeneca Plc (AZN)

43.87
0.26 0.59
NYSE : Health Technology
Prev Close 44.13
Open 44.18
Day Low/High 43.67 / 44.20
52 Wk Low/High 35.30 / 46.22
Volume 1.65M
Avg Volume 3.45M
Exchange NYSE
Shares Outstanding 2.62B
Market Cap 114.91B
EPS 0.80
P/E Ratio 19.79
Div & Yield 1.37 (3.10%)
4 Stocks to Avoid Amid the Mad 'Search for Yield'

4 Stocks to Avoid Amid the Mad 'Search for Yield'

There's a price to pay for low expectations.

Closing Bell: Tinder Boosts Match; Earnings Drive S&P 500 Higher

Closing Bell: Tinder Boosts Match; Earnings Drive S&P 500 Higher

Another busy day on the earnings calendar kept trading erratic again on Thursday, though the S&P 500 and Nasdaq managed to clinch slight gains by the end of the session.

AstraZeneca Likely to Grind Lower

Barring a strong rally over $31 that has follow-through, we look for AZN to slowly erode.

Bret Jensen Reporting for Duty

Good morning! Bret Jensen here! It's good to be standing in for Doug Kass on Doug's Daily Dairy this Friday, especially on a day when my "Best Idea" Relypsa (RLYP) is likely to soar. After the bell Thursday, the U.S. Food and Drug Administration ess...

2 Small-Cap Biotechs With Big Ambitions

2 Small-Cap Biotechs With Big Ambitions

Inovio Pharmaceuticals and Eagle Pharmaceuticals both boast solid pipelines and sound balance sheets.

Relypsa's Still a Bargain Despite 67% Rally

Small biotech has plenty of cash and a very valuable drug.

Relypsa's Still a Bargain Despite 67% Rally

Relypsa's Still a Bargain Despite 67% Rally

Small biotech has plenty of cash and a very valuable drug.

Tax Clampdown Prompts Pfizer to Scrap Allergan Purchase

CEO Read says the Viagra maker retains the means to pursue 'attractive business development' opportunities as he tears up the six-month-old deal with the maker of Botox.

Pfizer Tops Interbrand's List of Best Biopharmaceutical Brands

Pfizer Tops Interbrand's List of Best Biopharmaceutical Brands

Pfizer scored the top spot in Interbrand Health's inaugural ranking of the top ten biopharmaceutical brands.

Revisiting 3 Promising Small Biotechs

Revisiting 3 Promising Small Biotechs

They are oversold and lately been on the move.

Don't Throw This Biotech 'Baby' Out With the Bathwater

Drug maker Relypsa is poised for a huge upside, despite the current market sentiment.

Don't Throw This Biotech 'Baby' Out With the Bathwater

Don't Throw This Biotech 'Baby' Out With the Bathwater

Drug maker Relypsa is poised for a huge upside, despite the current market sentiment.

Biotech Stocks Are Beginning to Stir

Biotech Stocks Are Beginning to Stir

I am starting to get more confident that the small caps are ready to bounce.

AstraZeneca downgraded at Jefferies

AstraZeneca's Ailment Doesn't Look Treatable

AZN looks vulnerable to further declines. The next downside support area and price target are the $26-$24 area. 

2 Speculative Biotech Stocks for 2016

2 Speculative Biotech Stocks for 2016

Cempra and Relypsa are two high-risk, high-reward small-caps worth considering.

Asian, European Stocks Surge in the Morning of Fed Interest Rate Day

And four other things you need to know now.

Why Relypsa Is a New 'Best Idea'

Why Relypsa Is a New 'Best Idea'

It is hard to see the biotech firm not becoming a takeover target.

Greek Parliament Approves Reforms Required by Creditors

And four other things you need to know now.

Chinese Stocks Close Into Bull Market Territory

And four other things you need to know now.

4 Reasons to Buy High Dividend Yield Equities in Europe

As bond yields go negative, dividend yields shine. 

Searching for a Bottom in AstraZeneca; $34.50 Is the Critical Level

Our strategy for the stock is to look to buy available weakness in the next few weeks.

When Eyeing Small Biotechs, Partnerships Are Huge

When Eyeing Small Biotechs, Partnerships Are Huge

Key collaboration deals with deeper-pocketed concerns can improve the odds of investment success.

Overpriced and Vulnerable: 9 Stocks to Avoid

A look at the high-priced and weak among the most expensive sectors.

Dynavax: Revisiting A 'Best Idea'

Dynavax: Revisiting A 'Best Idea'

This small-cap biotech firm could be in the early stages of a big move.

China Forbids Big Shareholders to Sell Stocks for 6 Months

And four other things you need to know now.

Here Are 3 Charts Showing You Why Illumina Is a Marvel

It's almost impossible to get too excited about its success.

The Amazing Thing About the Receptos Takeover Chatter

That this could be such an open secret is beyond me.

Biotech Moves Are Anything But Crazy

New companies are coming up with major drugs.

Here Are 3 Stocks With Huge Potential

Two are biotechs and one is in cyber security.